Hemolytic Anemia — Approach and Classification

Hemolytic anemia is defined as a decrease in hemoglobin concentration resulting from accelerated destruction of circulating red blood cells (RBCs) with a lifespan of <120 days (normal 120 days). The clinical significance of hemolytic anemia lies in the body's inability to compensate adequately through increased erythropoiesis, resulting in symptomatic anemia despite elevated reticulocyte counts. Hemolytic anemias account for 1-3% of all anemias and occur across all demographics, though specific etiologies show distinct epidemiologic patterns (e.g., G6PD deficiency in African and Mediterranean populations, hereditary spherocytosis in Northern Europeans). Understanding hemolytic anemias is critical for clinical practice because they present acutely with dramatic laboratory and clinical findings and require rapid diagnosis to prevent life-threatening complications including acute kidney injury, disseminated intravascular coagulation (DIC), and cardiovascular collapse. For board examinations, hemolytic anemias are high-yield topics that frequently appear as case vignettes requiring systematic classification and targeted diagnostic reasoning.

Hemolytic anemia results from the pathologic destruction of RBCs through multiple mechanisms. The fundamental abnormality involves either intrinsic defects within the erythrocyte (intrinsic hemolysis) or external factors targeting the RBC (extrinsic hemolysis), leading to premature removal from circulation. Understanding the distinction between intrinsic and extrinsic causes is essential for diagnosis and determines the approach to classification and management.

Intrinsic hemolytic anemias result from inherited or acquired defects within the RBC itself that render the cell inherently fragile. In hereditary spherocytosis (HS), mutations in genes encoding membrane skeleton proteins (spectrin, ankyrin, band 3) cause progressive loss of membrane surface area with each passage through the spleen. The resultant spherical RBC has diminished deformability, cannot squeeze through the splenic microvasculature, and undergoes osmotic lysis due to increased surface-area-to-volume ratio. The osmotic fragility test becomes abnormally positive because these spherocytes lyse at higher osmotic pressures than normal biconcave RBCs.

In glucose-6-phosphate dehydrogenase (G6PD) deficiency, the intrinsic defect involves decreased pentose phosphate pathway activity, resulting in reduced NADPH production and impaired glutathione reduction. Without adequate reduced glutathione, oxidative stressors (infection, sulfonamides, fava beans, aspirin) overwhelm antioxidant defenses, causing hemoglobin oxidation to methemoglobin and precipitation into Heinz bodies. These inclusion bodies are removed by the spleen, creating bite cells and precipitating acute hemolytic crisis.

In hemoglobinopathies (sickle cell disease, thalassemia), structural or quantitative hemoglobin abnormalities directly impair RBC function. Sickle hemoglobin (HbS) polymerizes under low oxygen tension, creating rigid polymers that deform the RBC, cause vaso-occlusion, and trigger hemolysis through both extravascular (splenic sequestration) and intravascular mechanisms.

In hereditary elliptocytosis and pyropoikilocytosis, defects in spectrin-actin interactions create abnormally shaped RBCs with reduced deformability. Similarly, disorders of RBC enzymes (pyruvate kinase deficiency) impair glycolysis and ATP production, reducing the RBC's ability to maintain ion gradients and resist osmotic stress.

Extrinsic hemolytic anemias involve processes external to the RBC that target normal or near-normal erythrocytes. In autoimmune hemolytic anemia (AIHA), the immune system produces IgG or IgM antibodies against RBC antigens. IgG-coated RBCs are recognized by Fcγ receptors on splenic macrophages, leading to extravascular hemolysis through antibody-dependent cellular phagocytosis. Cold agglutinin disease involves IgM antibodies that bind RBCs at peripheral temperatures, activate complement (especially in peripheral extremities), and cause intravascular hemolysis with hemoglobinuria, whereas warm AIHA (IgG-mediated) predominantly causes extravascular hemolysis.

In alloimmunization (post-transfusion or hemolytic disease of the newborn), donor RBC antigens not present on recipient RBCs trigger both IgG and IgM responses, leading to accelerated destruction particularly during the second and subsequent transfusions.

In drug-induced hemolytic anemia, three mechanisms predominate: (1) drug adsorption, where drugs (penicillin) coat RBC membranes and elicit IgG antibodies against the drug-RBC complex; (2) immune complex formation, where drug-antibody complexes deposit on RBCs and activate complement; and (3) drug-independent antibodies, where medications (methyldopa) trigger antibodies against intrinsic RBC antigens.

In microangiopathic hemolytic anemia (MAHA), mechanical trauma from fibrin strands deposited in the microvasculature (DIC, thrombotic thrombocytopenic purpura [TTP], hemolytic uremic syndrome [HUS]) or abnormal heart valves (prosthetic valves, severe aortic stenosis) shears RBCs, creating fragmented RBCs (schistocytes). The reduced lifespan of these fragmented cells and ongoing damage precipitate hemolysis.

In hemolytic anemia, the bone marrow recognizes anemia and hypoxia, triggering increased erythropoietin (EPO) production by peritubular fibroblasts in the kidney. EPO stimulates erythroid progenitors, leading to accelerated RBC maturation and release of immature RBCs (reticulocytes) into circulation earlier than normal. The reticulocyte count becomes markedly elevated (often >10-15%), representing the body's compensatory attempt to maintain hemoglobin levels.

However, if hemolysis is severe and outpaces compensatory erythropoiesis, or if bone marrow function is impaired (aplastic crisis in sickle cell disease, parvovirus B19 infection suppressing erythropoiesis), anemia develops despite elevated reticulocyte responses. The reticulocyte production index (RPI) quantifies bone marrow response: RPI = (reticulocyte count × patient Hgb/normal Hgb) / (maturation time correction). An RPI >2-3 confirms appropriate bone marrow response to hemolysis, whereas RPI <2 suggests impaired bone marrow compensation or concurrent bone marrow suppression.

In chronic hemolytic anemias, the spleen undergoes compensatory hyperplasia, increasing its capacity to filter and destroy abnormal RBCs. This splenic enlargement (splenomegaly) becomes a hallmark physical finding in chronic hemolytic anemias. Additionally, the splenic macrophages increasingly take up aged and damaged RBCs, liberating hemoglobin. Within macrophages, hemoglobin is degraded to bilirubin through sequential enzymatic steps: hemoglobin → globin + heme; heme → biliverdin + carbon monoxide (CO); biliverdin → bilirubin. This unconjugated hyperbilirubinemia elevates indirect bilirubin levels, predisposing to bilirubin gallstones (pigmented stones) and cholecystitis in chronic hemolytic anemias.

When hemolysis is severe and predominantly intravascular, free hemoglobin is released directly into plasma. Plasma hemoglobin is rapidly bound by haptoglobin, depleting this acute-phase reactant. Unbound hemoglobin is filtered by the kidneys and oxidized to methemoglobin in the proximal tubule, which is reabsorbed by proximal tubular cells as hemosiderin. This hemosiderin accumulation in tubular cells is shed and appears in the urine as hemosiderin casts. If filtered hemoglobin exceeds the renal reabsorptive capacity, dark-colored hemoglobinuria develops, conferring a characteristic tea- or cola-colored appearance to the urine.

Hemolytic anemias are systematically classified by distinguishing intrinsic (inherited or acquired defects of the RBC) from extrinsic (immune or mechanical destruction) causes. This classification framework is fundamental to the diagnostic approach and guides investigation strategy.

Hereditary spherocytosis (HS) represents the most common inherited hemolytic anemia in Northern European populations (incidence 1 in 2,000 to 1 in 4,500). Autosomal dominant inheritance predominates (~75% of cases), though autosomal recessive and de novo mutations occur. HS results from mutations in genes encoding membrane skeleton proteins, particularly spectrin (SPTA1, SPTB), ankyrin (ANK1), band 3 (SLC4A1), protein 4.2, and RhAG. These defects disrupt the vertical and horizontal links between the lipid bilayer and underlying spectrin network, causing progressive membrane instability. With each passage through the splenic microcirculation, the osmotically stressed membrane loses lipid and surface area, progressively converting the normal biconcave RBC into a rigid sphere with increased osmotic fragility.

Hereditary elliptocytosis (HE) and hereditary pyropoikilocytosis represent variants with defects in spectrin-actin junctional complexes, causing elongated or fragmented RBC shapes and variable degrees of hemolysis.

Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most common enzymatic RBC disorder worldwide, affecting approximately 400 million people, particularly those of African (African variant, Class III; mild hemolysis), Mediterranean (Mediterranean variant, Class II; severe hemolysis), and Asian descent. G6PD deficiency is X-linked recessive, explaining its predominance in males and carrier status in heterozygous females (though manifesting heterozygotes with skewed X-inactivation exist). The enzyme catalyzes the first committed step of the pentose phosphate pathway, generating NADPH needed to maintain reduced glutathione. Without adequate NADPH, oxidative stressors (infection, drugs—sulfonamides, dapsone, primaquine, aspirin—fava beans, or rarely, severe exercise) precipitate hemolytic crises. Hemolysis is typically self-limited after removal of the offending agent, as older RBCs with lower G6PD activity are preferentially destroyed.

Pyruvate kinase (PK) deficiency is an autosomal recessive glycolytic enzyme defect affecting approximately 1 in 20,000 individuals. PK catalyzes the final committed step of glycolysis, and its deficiency impairs ATP production, reducing the RBC's ability to maintain the Na+/K+-ATPase gradient. Chronic hemolysis results, often complicated by hemolytic crises during infection. Unlike G6PD deficiency, PK deficiency causes chronic, baseline hemolysis rather than episodic crises.

Other glycolytic defects (hexokinase, phosphofructokinase, triose phosphate isomerase) are rare but should be considered in cases of congenital non-immune hemolytic anemia.

Sickle cell disease (SCD) results from a point mutation in the β-globin gene (Glu6Val), producing hemoglobin S (HbS). Homozygous SCD affects approximately 70,000-100,000 Americans, predominantly African Americans (1 in 300-400 African Americans). HbS polymerizes under deoxygenated conditions, distorting the RBC into a characteristic "sickle" shape with reduced deformability. Polymerization triggers both intravascular hemolysis (direct RBC injury from polymers) and extravascular hemolysis (splenic sequestration of rigid sickled RBCs). Hemoglobin SS patients have a baseline hemoglobin of 7-10 g/dL with a reticulocyte count of 5-15%, indicating chronic compensated hemolysis. Acute hemolytic crises can be precipitated by hypoxia, infection, or dehydration, presenting with severe anemia and reticulocytopenia paradoxically due to parvovirus B19 infection.

Thalassemia major (homozygous α or β thalassemia) results from absent or severely reduced production of globin chains, causing severe microcytic hemolytic anemia. Unbalanced globin chains precipitate as inclusion bodies, triggering hemolysis and ineffective erythropoiesis.

Other hemoglobinopathies (Hb C disease, Hb E disease) rarely cause significant hemolysis in homozygotes but may do so in compound heterozygotes (e.g., Hb SC disease).

PNH is an acquired clonal disorder of the hematopoietic stem cell resulting from somatic mutation in the PIGA gene (phosphatidylinositol glycan anchor biosynthesis class A). This mutation leads to absent or reduced expression of glycosylphosphatidylinositol (GPI)-anchored complement regulatory proteins, particularly CD55 (decay-accelerating factor) and CD59 (membrane inhibitor of reactive lysis). Without these regulators, complement (especially the alternate pathway) is uncontrolled, causing direct lytic injury to the RBC membrane. Hemolysis occurs intravascularly, particularly at night (hence "nocturnal") when complement is most active. PNH presents with dark urine (hemoglobinuria), chronic hemolytic anemia, and a distinctive thrombophilic tendency (venous thromboembolism, particularly hepatic vein thrombosis).

Warm AIHA is the most common form of immune hemolytic anemia, caused by IgG antibodies that bind RBCs optimally at 37°C (body temperature). Warm AIHA may be primary (idiopathic, 50% of cases) or secondary to lymphoproliferative disorders (chronic lymphocytic leukemia, lymphoma), autoimmune diseases (systemic lupus erythematosus, rheumatoid arthritis), or medications (methyldopa, penicillin). IgG-coated RBCs are recognized by Fcγ receptors on splenic macrophages, leading to extravascular hemolysis predominantly in the spleen (hence splenomegaly). The Direct Coombs test (direct antiglobulin test, DAT) is positive for IgG, often with reduced complement. Hemolysis is typically chronic and moderate in severity.

Cold agglutinin disease is caused by IgM antibodies (rarely IgG) that bind RBCs at peripheral temperatures (4-20°C) but dissociate at core body temperature. IgM-bound RBCs activate complement, particularly at the periphery (fingers, toes, nose, ears), causing intravascular hemolysis. Cold agglutinin disease presents with hemoglobinuria after cold exposure, Raynaud-like phenomena, and severe anemia. The DAT is positive for complement (C3) only, with negative or weak IgG, distinguishing it from warm AIHA. Primary cold agglutinin disease occurs idiopathically in elderly patients, whereas secondary forms follow infections (mycoplasma, Epstein-Barr virus [EBV], cytomegalovirus [CMV]) or lymphoproliferative disorders (lymphoma, macroglobulinemia).

Penicillin and penicillin-derived antibiotics act as haptens, binding RBC membranes. The immune system generates IgG antibodies against the penicillin-RBC complex, leading to complement-independent extravascular hemolysis. Large penicillin doses increase hapten density on RBCs, amplifying the hemolytic response.

Methyldopa and other drugs (levodopa, quinidine) induce "true" drug-independent antibodies against intrinsic